• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Insights / Webinars

Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

Written on Tuesday, November 12, 2024

Missed our recent webinar on the role of AI in Joint Clinical Assessments (JCAs)? Catch the webinar recording. It will benefit stakeholders involved in health technology assessment (HTA), artificial intelligence (AI) development, and AI regulation by providing a comprehensive debate on the use of AI in JCAs.

Starting in January 2025, as part of the EU HTA regulation, all new oncology and advanced therapy medicinal products will be subject to JCA. As stipulated in the JCA Implementing Act, systematic literature review (SLR) searches should be no older than three months, while the final scope of the JCA will only be issued 100 days prior to the submission deadline. This compressed timeline presents a challenge to ensure SLRs are conducted quickly while maintaining the rigor required for HTA.

The integration of AI in SLRs presents an opportunity to improve the efficiency and accuracy of evidence generation for JCAs. This webinar will explore how AI can support evidence generation for JCAs and consider the potential benefits and challenges of this approach.

The webinar discussion will address the following key questions:

  • How can AI tools increase the efficiency of SLRs for JCAs while maintaining quality?
  • What are the possible challenges and barriers to implementing AI for SLRs?
  • What will it take for HTA organizations to accept AI-supported SLRs? Are there differences in national perspectives?

Moderator:

  • Grace Fox, Associate Director – Strategic Market Access, OPEN Health, United States

Speakers:

  • Emanuele Arcà, Scientific Office Lead – Strategic Market Access, OPEN Health, The Netherlands
  • Farhad Shokraneh, Evidence Synthesis Manager, Oxford University, United Kingdom
  • Susanne Hartz, Director, Global Health Outcomes/HTA International, Eli Lilly and Company, United Kingdom

 

 


Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. Together we can unlock possibilities. For information about OPEN Health’s services and how we could support you, please get in touch.

Contact us

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top